HepaLife said that its subsidiary, Alliqua BioMedical (Alliqua), recently retained Jeiven Pharmaceutical Consulting (Jeiven) to assist it in this new product development.

Through this partnership, Alliqua intends to pursue a generic version of an existing pain management patch for the treatment of postherpetic neuralgia (PHN).

Alliqua CEO Matthew Harriton said that they believe that their existing expertise in manufacturing these products, combined with the developmental and regulatory experience that Jeiven brings to this project would prove invaluable, and would help them realise commercialisation in a timely and cost effective manner.

“Utilising HepaLife’s proprietary hydrogel technology, we believe Alliqua can become a low cost producer of this transdermal pain patch,” Harriton said.

Jeiven vice president and chief scientific officer Ashutosh Sharma said that they were excited to join the Alliqua team in this project.

“By combining Jeiven’s resources and experience in pharmaceutical product development, with HepaLife’s proprietary technology, we believe Alliqua has a great opportunity for a relatively low risk product launch with the possibility for significant gain in market share,” Sharma said.